


## Curriculum Vitae

|                                                                                   |                                                       |                                     |
|-----------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------|
|  | <b>Name</b><br>(First Name / Middle Name / Last Name) | <b>Stephan R. Targan, MD</b>        |
|                                                                                   | <b>Title</b><br>(Prof. Dr., etc.)                     | Distinguished Professor of Medicine |
|                                                                                   | <b>Affiliation</b>                                    | <b>Cedars-Sinai Medical Center</b>  |
|                                                                                   | <b>Country</b>                                        | USA                                 |
|                                                                                   | <b>E-mail</b>                                         | stephan.targan@cshs.org             |

### Educational Background

*B.A. Johns Hopkins University, Baltimore, Maryland-1967*  
*M.D. Johns Hopkins University, Baltimore, Maryland-1971*  
*Harbor-UCLA Medical Center, Torrance, California 1972-1974*  
*Division of Infectious Diseases, Harbor-UCLA Medical Center,*  
*Torrance, California 1974-1976*  
*Division of Gastroenterology, UCLA School of Medicine, Los Angeles,*  
*California 1976-1978*  
*Immunology Fellowship, UCLA School of Medicine, 1977-1978*

### Professional Career

*2025 – present: Executive Director, F. Widjaja Inflammatory Bowel Disease Institute; Professor of Medicine*  
*2020 – present: Distinguished Professor, Medicine, Cedars-Sinai*  
*1992 – present: Feintech Family Chair in Inflammatory Bowel Disease*  
*2008 – present: Distinguished Professor of Medicine (Gastroenterology) in Residence Further*  
*Above Scale - 3, UCLA School of Medicine, Los Angeles, California*

### Research Field

Basic, Translation, Clinical Research in IBD  
 Immunology, Biomarker Discovery, Drug Development

### Main Scientific Publications

Out of 400 published manuscripts

Targan S, Decker JM, Ades EW. Mechanism of Inhibition of Natural Killing by a Glycopeptide Isolated from the K562 Plasma Membrane. *Nat Immun Cell Growth Regul.* 1983;3:113-23.

Elson CO, Kagnoff MF, Fiocchi C, Befus AD, Targan SR. Intestinal Immunity and Inflammation: Recent Progress. *Gastroenterology.* 1986;91(3):746-68.

Saxon A, Shanahan F, Landers C, Ganz T, Targan SR. A Distinct Subset of Antineutrophil Cytoplasmic Antibodies is Associated with Inflammatory Bowel Disease. *J Allergy Clin Immunol.* 1990;86:202-10.

Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, Landers CJ, Targan SR. Neutrophil Autoantibodies in Ulcerative Colitis: Familial Aggregation and Genetic Heterogeneity. *Gastroenterology.* 1992 Aug;103(2):456-61.

Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative Colitis: A Genetically Heterogeneous Disorder Defined by Genetic (HLA Class II) and Subclinical (Antineutrophil Cytoplasmic Antibodies) Markers. *J Clin Invest.* 1993 Aug;92:1080-4.

Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A Short-term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor Alpha for Crohn's Disease: Crohn's Disease cA2 Study Group. *N Engl J Med.* 1997 Oct 9;337(15):1029-35.

Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn's Disease. *Gastroenterology.* 2001;120(6):1347-55.

Fleshner PR, Vasilias EA, Kam LY, Fleshner N, Gaiennie J, Abreu-Martin MT, Targan SR. High level Perinuclear ANCA in Ulcerative Colitis Patients Before Colectomy Predicts the Development of Chronic Pouchitis After Ileal Pouch-anal Anastomosis. *Gut.* 2001 Nov;49(5):671-7.

Mow WS, Vasilias EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JL, Yang H, Targan SR. Association of Antibody Responses to Microbial Antigens and Complications of Small Bowel Crohn's Disease. *Gastroenterology.* 2004 Feb;126(2):414-24.

Papadakis KA, Prehn JL, Landers C, Han Q, Lou X, Cha SC, Wei P, Targan SR. TL1A Synergizes with IL-12 and IL-18 to Enhance IFN-gamma Production in Human T Cells and NK Cells. *Immunol.* 2004 Jun 1;172(11):7002-7.

Papadakis KA, Zhu D, Prehn JL, Landers C, Avanesyan A, Lafkas G, Targan SR. Dominant Role for TL1A/DR3 Pathway in IL-12 Plus IL-18-induced IFN-gamma Production by Peripheral Blood and Mucosal CCR9+ T lymphocytes. *J Immunol.* 2005 Apr 15;174(8):4985-90.

Melmed GY, Elashoff R, Chen GC, Nastaskin I, Papadakis KA, Vasiliauskas EA, Liu W, Landers C, Ippoliti A, Targan SR. Predicting a Change in Diagnosis from Ulcerative Colitis to Crohn's Disease: A Nested, Case-control Study. *Clin Gastroenterol Hepatol*. 2007 May 5(5):602-8.

Melmed G, Fleshner P, Bardakcioglu O, Ippoliti A, Vasiliauskas E, Papadakis K, Dubinsky M, Landers C, Rotter J, Targan SR. Family History and Serology Predict Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulcerative Colitis. *Disease of the Colon and Rectum*. 2008 Jan;51(1):100-8. PMID: 18085333. PMCID: PMC2442922

Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ, Derkowski C, McGovern DP, Rotter JI, Targan SR. IBD-associated TL1A Gene (TNFSF15) Haplotypes Determine Increased Expression of TL1A Protein. *PLoS ONE*. Epub 2009 Mar 5. 2009;4(3):e4719. PMID: 19262694 PMCID: PMC2648040

Plevy SE, Targan SR. Future Therapeutic Approaches for Inflammatory Bowel Diseases. *Gastroenterology*. 2011 May;140(6):1838-46. PMID: 21530750. PMCID: PMC5076881

Barrett R, Zhang X, Koon HW, Vu M, Chang J, Yeager N, Nguyen M, Michelsen K, Berel D, Pothoulakis C, Targan SR, Shih DQ. Constitutive TL1A Expression Under Colitogenic Conditions Modulates the Severity and Location of Gut Mucosal Inflammation and Induces Fibrostenosis. *Am J Pathol*. Epub 2011 Dec 2. 2012 Feb;180(2):636-49. PMID: 22138299. PMCID: PMC3349869

Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace K, Chen J, Pothoulakis C, Koon HW, Targan SR. Inhibition of a Novel Fibrogenic Factor Tl1a Reverses Established Colonic Fibrosis. *Mucosal Immunol*. Epub 2014 May 21. 2014 Nov;7(6):1492-503. PMID: 24850426. PMCID: PMC4205266

Gonsky R, Fleshner P, Deem RL, Biener-Ramanujan E, Li D, Potdar AA, Bilsborough J, Yang S, McGovern DPB, Targan SR. Association of Ribonuclease T2 Gene Polymorphisms with Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease. *Gastroenterology*. 2017 Apr;153(1):219-32. PMID: 28400196. PMCID: PMC5484733